The FDA approved Sucampo Pharmaceuticals Inc.'s Amitiza (lubiprostone) for female patients with constipation-predominant irritable bowel syndrome (IBS-C), making it the only U.S.-approved drug for that indication following the marketing suspension of Novartis AG's Zelnorm last year. (BioWorld Today) Read More
